BEAMBeam Therapeutics Inc.

$3B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$763,000+12616.7% YoY

Gross Profit

-$54M-7059.0% margin

Operating Income

-$70M-9126.3% margin

Net Income

-$28M-3685.2% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

+12616.7%

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$303M

Stockholders' Equity

$854M

Cash & Equivalents

$612M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$763,000	$6,000	+12616.7%
Gross Profit	-$54M	-$30M	-80.6%
Operating Income	-$70M	-$37M	-86.6%
Net Income	-$28M	-$34M	+18.4%

BEAM Q3 2021 Earnings — Beam Therapeutics Inc. Revenue & Financial Results | Market Cap Arena